Panacea Biotec, one of India’s leading biotechnology companies, is proud to announce two major developments: the launch of the world’s first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol, in India and the registration of Valganciclovir 50 mg/ml Powder for Oral Solution in Germany by its subsidiary, Panacea Biotec Germany GmbH. EasyFourPol is a milestone in paediatric […]
Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine manufacturing facility at its Canadian headquarters, Sanofi Pasteur, in Toronto. This development is aimed at bolstering the company’s operational capabilities in Canada and reaffirming its commitment to advancing global public […]
